Work

A phase I study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, for intravenous (IV) administration in patients with advanced solid tumors

Year: 2016

Type: article

Source: European Journal of Cancer

DOI: 10.1016/s0959-8049(16)32645-4

Authors: A. Razak, L. Gore, C.D. Britten, W.H. Miller, G.L. Uy, G. Nichols, S. Middleton, S. Blotner, J. Zhi, L. Jukofsky, W. Pierceall, B. Higgins, L.C. Chen

Language: English

Topic: Cancer-related Molecular Pathways

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2560029090

FWCI: 0.72

Cites:

Cited by: 5

Related to: 10